Approximately 112 million people globally are affected by angina and undergo coronary angiography, the primary diagnostic test for angina.1
Too often patients with ischemia and no obstructive coronary artery disease (INOCA) on angiography — remain undiagnosed.2
Coronary Microvascular Dysfunction (CMD)3 is defined as impaired blood flow to the microcirculation. A clear diagnosis and optimized treatment plan can improve outcomes for these patients at high risk for major adverse events (MACE).4
The CorMicA (CORonary MICrovascular Angina) study revealed that patients may benefit when CMD is accurately diagnosed and appropriately treated:4
Ischemic heart disease continues to be the leading cause of death globally.11 Yet chest pain—while often ischemic in nature—could have many etiologies, as illustrated.3 When chest pain is caused by ischemia, proper management depends on accurately identifying and treating the underlying cause of angina.
Only 41% of patients assessed for angina are found to have obstructive chronic Coronary Artery Disease.13 The majority, 59% of patients, assessed for angina are found to have no angiographic abnormalities, but still have symptoms of a coronary disorder.4,5
*According to the Seattle Angina Questionnaire score.
You are about to enter an Abbott country- or region-specific website.
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions
Do you wish to continue and enter this website?